Journal: International Wound Journal

Article Title: Efficacy and safety of recombinant human epidermal growth factor for diabetic foot ulcers: A systematic review and meta‐analysis of randomised controlled trials

doi: 10.1111/iwj.13377

Figure Lengend Snippet: Interventional details of included trials

Article Snippet: Tsang et al. 2003 , I1: rhEGF 0.02% ( n = 21) I2: rhEGF 0.04% ( n = 21) , Actovegin 5% cream ( n = 19) , Topical application , NA , 12 wk , Every other week , 24 wk , I1 = 57.1% (12/21) I2 = 95.0% (20/21) C = 42.1% (8/19) , Illustrated with Kaplan‐Meier curve.

Techniques: Control, Saline, Injection, Cream

Journal: International Wound Journal

Article Title: Efficacy and safety of recombinant human epidermal growth factor for diabetic foot ulcers: A systematic review and meta‐analysis of randomised controlled trials

doi: 10.1111/iwj.13377

Figure Lengend Snippet: Kaplan‐Meier curves of time to complete healing (rhEGF group)

Article Snippet: Tsang et al. 2003 , I1: rhEGF 0.02% ( n = 21) I2: rhEGF 0.04% ( n = 21) , Actovegin 5% cream ( n = 19) , Topical application , NA , 12 wk , Every other week , 24 wk , I1 = 57.1% (12/21) I2 = 95.0% (20/21) C = 42.1% (8/19) , Illustrated with Kaplan‐Meier curve.

Techniques:

Journal: International Wound Journal

Article Title: Efficacy and safety of recombinant human epidermal growth factor for diabetic foot ulcers: A systematic review and meta‐analysis of randomised controlled trials

doi: 10.1111/iwj.13377

Figure Lengend Snippet: Adverse events

Article Snippet: Tsang et al. 2003 , I1: rhEGF 0.02% ( n = 21) I2: rhEGF 0.04% ( n = 21) , Actovegin 5% cream ( n = 19) , Topical application , NA , 12 wk , Every other week , 24 wk , I1 = 57.1% (12/21) I2 = 95.0% (20/21) C = 42.1% (8/19) , Illustrated with Kaplan‐Meier curve.

Techniques: Infection

Journal: Molecular carcinogenesis

Article Title: Soluble-E-Cadherin Activates HER and IAP Family Members in HER2+ and TNBC Human Breast Cancers

doi: 10.1002/mc.22048

Figure Lengend Snippet: sEcad exerts additive effects with EGF to promote oncogenicity (A) MCF-7 cells were starved for 4 h in serum-free medium and treated with vehicle control (C), rhEGF (500 ng/ml), rhEcad/Fc (10 µg/ml), or rhEGF and rhEcad/Fc in combination for 24 h, and cellular proliferation was assessed using an ELISA BrdU (colorimetric) assay. Results are presented as mean ± SEM. (B) Effect of 22-h incubation of rhEGF (500 ng/ml), rhEcad/Fc (10 µg/ml), and rhEGF + rhEcad/Fc on MCF-7 migration. Cells that migrated through the control insert were fixed, stained, photographed and counted in ten random high-power fields per insert. Results are presented as mean ± SEM of fold change in rhEGF, rhEcad/Fc, and rhEGF + rhEcad/Fc treated cells compared with vehicle control (C). All quantitative data were generated from a minimum of three replicates. (C) Invasion of MDA-MB-231 cells in the presence or absence of equimolar concentrations of rhEGF (1 µg/ml), rhEcad/Fc (20 µg/ml), or rhEGF and rhEcad/Fc in combination for 22 h. Cells that invaded the Matrigel layer were fixed, stained, photographed and counted in ten random high-power fields per insert. Results are presented as mean ± SEM of fold change in rhEGF, rhEcad/Fc, and rhEGF + rhEcad/Fc treated cells compared with vehicle control (C). All quantitative data were generated from a minimum of three replicates. Insert: Representative 0.5% crystal violet staining of MDA-MB-231 cells treated with Vehicle, rhEGF, rhEcad/Fc, or rhEGF + rhEcad/Fc. (D) Immunoblotting of phospho-HER-MAPK-PI3K/Akt/mTOR and IAP family members in MCF-7 cells after incubation with equimolar concentrations of rhEGF (500 ng/ml), rhEcad (10 µg/ml), and rhEGF and rhEcad/Fc in combination for 24 h.

Article Snippet: Recombinant human EGF (rhEGF) was purchased from Enzo Life Sciences (Farmingdale, NY).

Techniques: Enzyme-linked Immunosorbent Assay, Colorimetric Assay, Incubation, Migration, Staining, Generated, Western Blot

Journal: International Wound Journal

Article Title: Efficacy and safety of recombinant human epidermal growth factor for diabetic foot ulcers: A systematic review and meta‐analysis of randomised controlled trials

doi: 10.1111/iwj.13377

Figure Lengend Snippet: Interventional details of included trials

Article Snippet: Tsang et al. 2003 , I1: rhEGF 0.02% ( n = 21) I2: rhEGF 0.04% ( n = 21) , Actovegin 5% cream ( n = 19) , Topical application , NA , 12 wk , Every other week , 24 wk , I1 = 57.1% (12/21) I2 = 95.0% (20/21) C = 42.1% (8/19) , Illustrated with Kaplan‐Meier curve.

Techniques: Control, Saline, Injection, Cream

Journal: International Wound Journal

Article Title: Efficacy and safety of recombinant human epidermal growth factor for diabetic foot ulcers: A systematic review and meta‐analysis of randomised controlled trials

doi: 10.1111/iwj.13377

Figure Lengend Snippet: Kaplan‐Meier curves of time to complete healing (rhEGF group)

Article Snippet: Tsang et al. 2003 , I1: rhEGF 0.02% ( n = 21) I2: rhEGF 0.04% ( n = 21) , Actovegin 5% cream ( n = 19) , Topical application , NA , 12 wk , Every other week , 24 wk , I1 = 57.1% (12/21) I2 = 95.0% (20/21) C = 42.1% (8/19) , Illustrated with Kaplan‐Meier curve.

Techniques:

Journal: International Wound Journal

Article Title: Efficacy and safety of recombinant human epidermal growth factor for diabetic foot ulcers: A systematic review and meta‐analysis of randomised controlled trials

doi: 10.1111/iwj.13377

Figure Lengend Snippet: Adverse events

Article Snippet: Tsang et al. 2003 , I1: rhEGF 0.02% ( n = 21) I2: rhEGF 0.04% ( n = 21) , Actovegin 5% cream ( n = 19) , Topical application , NA , 12 wk , Every other week , 24 wk , I1 = 57.1% (12/21) I2 = 95.0% (20/21) C = 42.1% (8/19) , Illustrated with Kaplan‐Meier curve.

Techniques: Infection